Pan-India Translational Research Feasibility
Single-Cell & Spatial Omics, Metabolomics, CRISPR, Biocompatibility and Preclinical Research — Feasibility Review in Hyderabad
Discuss an integrated life-sciences research question with Dr. Chathyushya K B's team. Named techniques and platforms below are examples for feasibility review, not a claim that every assay, instrument, model, accreditation or partner arrangement is currently available. Cell-line work at Manna Biotech and any specialist or external work require confirmation. Eligible animal work may be coordinated for execution at an external facility under an MoU, subject to verified capability and applicable approvals.
- Scientist-guided, founder-led
- Research and industrial R&D
- Nacharam, Hyderabad · India-wide sample enquiries
1. Single-cell, spatial and epigenomics
Scope the specimen, platform and biological question.
Fresh-tissue handling, single-nuclei RNA-seq from frozen tissue, instrumentation and sample acceptance need prior confirmation; a platform name is not a promise of access.
Single-cell and spatial questions
Discuss scRNA-seq, snRNA-seq, 10x Genomics, Drop-seq, Nanopore full-length isoforms, scTCR/scBCR immune repertoire, CITE-seq, scATAC-seq and spatial transcriptomics. Check tissue quality, collection permissions, appropriate facilities and workflow availability before acceptance.
Analysis approaches
Subject to data and licensing, proposed workflows can include Seurat, Scanpy, Harmony, UMAP/t-SNE, Monocle3, scVelo, CellChat, NicheNet and SCENIC. Select methods, interpretive limits and handover deliverables with the reviewer.
Epigenomics and regulatory RNA
WGBS DNA methylation, ChIP-seq, CUT&Tag, ATAC-seq, miRNA, lncRNA, circRNA, and research-use cfDNA, ctDNA, ddPCR or exosomal miRNA are scoping requests; confirm available facilities, specimen permissions and intended use.
2. Metabolomics, lipidomics and proteomics
Define matrices, controls and analysis access.
Metabolite and lipid questions
Discuss targeted or untargeted LC-MS/MS and GC-MS metabolomics, lipidomics, short-chain fatty acids, bile acids and amino acids. Instrument access, method performance and matrices require project-specific confirmation.
Proteomics and integrated data
Review feasibility of 2D-PAGE, shotgun proteomics, peptide mass fingerprinting and transcriptome/proteome/metabolome integration. Research plasma, serum, urine, CSF, fecal or organ specimens require prior documented sample and facility acceptance.
3. Microbiome, phage and antimicrobial resistance
Clarify organisms, permissions and biosafety before any transfer.
Sequencing and resistance
Discuss Nanopore WGS, 16S/ITS and shotgun metagenomics, antimicrobial resistance gene panels and biofilm endpoints including MBEC, subject to organism, method, facility and biosafety review.
Phage and in-vivo research
Phage isolation, lytic spectrum, cocktail formulation and phage genome sequencing, and proposed dysbiosis, colitis, gut-axis, infected wound, sepsis or phage-rescue models require separate specialist and approved-facility review. No model or clinical therapy is guaranteed.
Gut and infection model enquiries
Discuss the research question for proposed antibiotic-induced dysbiosis, DSS/TNBS colitis, gut-brain or gut-liver models, or MDR/MRSA wound and sepsis endpoints. Appropriate biosafety, a capable approved facility and study-specific permissions must be confirmed before any work or material transfer.
4. Gene editing and advanced cell biology
Start with model and instrument feasibility.
Molecular and cellular techniques
Discuss CRISPR/Cas9 knockout, Perturb-seq, cloning, recombinant proteins, SDS-PAGE, zymography, Northern/dot/slot/Western blots, SNP-RFLP, in-situ hybridization and reporter assays. Expertise, licensing and method access must be confirmed.
Cell models and analysis
Review exosome isolation, 3D spheroid/organoid cytotoxicity, osteogenic, chondrogenic or adipogenic stem-cell differentiation, MTT/SRB/IC50, apoptosis, ROS, DNA fragmentation, flow cytometry or confocal imaging against specific cell lines, instruments, controls and permissions.
Oncology and biodistribution questions
Proposed EAC, DLA, xenograft or syngeneic animal models and nanoparticle, exosome or liposome biodistribution require external facility and applicable approval verification; availability is not implied.
5. Computational discovery and disease models
Separate predictions from experimental evidence.
AI, CADD and immunoinformatics
Discuss AI/ML molecular generation, QSAR, structure prediction including AlphaFold 3, docking, molecular dynamics, MM-PBSA, pharmacophore, FBDD, ADMET/TOPKAT, reverse vaccinology and network pharmacology, subject to tool access, licensing and fit.
Vaccine and pharmacology research
For proposed IgG/IgM, cytokine, splenocyte or vaccine studies, and antidiabetic, anti-obesity, hepatoprotective, nephroprotective, cardioprotective, anti-arthritic, anti-inflammatory, analgesic, anti-ulcer or neurobehavioral models, confirm project-specific expertise, animal facility and all applicable approvals.
Immunology and behavioral endpoints
Feasibility enquiries may cover neutralizing antibodies, IFN-gamma, TNF-alpha, IL-2, IL-4, IL-6 or IL-10, and proposed Morris water maze, elevated plus maze, Y-maze, rotarod or forced-swim endpoints. A named endpoint does not confirm the expertise, animal model or facility; verify them and applicable approvals in the written scope.
6. Chemistry, analytical and ADME/PK
Agree methods, controls, reporting and the executing laboratory.
Formulation and analytics
Discuss phytochemical isolation, custom synthesis, polymeric/lipid nanoparticles, HPLC, GC-MS, LC-MS/MS, FTIR, ICH stability, forced degradation and impurity profiling. Facility and validated methods must be separately verified.
In-vitro ADME and pharmacokinetics
Caco-2 permeability, microsomal stability, CYP450 inhibition, protein binding and blood-brain-barrier models, or rodent PK/PD, bioavailability, Cmax, Tmax, AUC, half-life, clearance and metabolite identification are feasibility enquiries—not confirmed capabilities.
7. Genotoxicity, devices and alternative models
Regulatory use requires a facility with the correct verified scope.
Genotoxicity and biocompatibility
Discuss OECD 471 Ames, chromosomal aberration, comet, OECD 474/475 animal genotoxicity and ISO 10993 cytotoxicity, hemocompatibility, sensitization, irritation, systemic toxicity or implantation. Confirm the applicable current standard, animal approvals, laboratory accreditation and intended regulatory use separately.
Toxicity and device-testing scope
Enquire about OECD 423/425 acute and proposed 28- or 90-day repeated-dose studies, and ISO 10993-4/5 hemocompatibility or cytotoxicity. Sensitization, irritation, systemic toxicity and implantation require review of the current applicable ISO parts, device category, approved facility and whether a report is suitable for its intended use.
Dermal, ophthalmic and alternative models
Anti-tyrosinase, anti-elastase/collagenase or SPF assay enquiries, proposed alopecia, psoriasis, dermatitis, acne, dry-eye, cataract or retinopathy models, zebrafish embryo toxicity (OECD 236), teratogenicity, cardiotoxicity or neuro-locomotion, and C. elegans aging or neuroprotection require model, specialist facility and ethical review before acceptance.
8. Bioinformatics, biostatistics and academic support
Plan reproducible analysis and ethical, author-led outputs.
Research datasets and analysis
Discuss authorised FASTQ/Cell Ranger, Seurat, Scanpy, proteomics and metabolomics data, GEO/SRA reanalysis, feasible qPCR validation, PRISMA systematic reviews and meta-analyses, and R/SPSS/GraphPad statistical support, subject to data access and expertise.
Study planning and scholarly outputs
Discuss sample-size rationale and 3Rs principles with the approving institution, and author-led manuscript or patent-data support. Researchers retain authorship and responsibility; patent filing requires an appropriately qualified professional and no approval or publication is guaranteed.
Pan-India enquiry and sample workflow
Begin with a non-identifying scope and consult the team. Send FASTQ or other authorised data only by an agreed secure route. Cryopreserved tissue, biofluids, medical devices and compounds require written receiving-facility acceptance, biosafety and carrier-approved transport instructions before dispatch.
Research-grade scope and clear reporting boundaries.
Methods, platforms, specialist instruments and services listed are feasibility topics, not guaranteed capacity or a claim of clinical, diagnostic, GLP, NABL, ISO or regulatory accreditation. Cell-line work at Manna Biotech depends on the method, materials, expertise and instrument. Eligible animal studies may be coordinated at an external facility under an MoU only after study-specific capability and applicable IAEC/CCSEA and other permissions are verified. Do not send patient identifiers or samples without written instructions.
Sample suitability, the executing facility, method availability, biosafety, acceptance criteria and deliverables are confirmed in writing before work begins. We do not guarantee a particular result, publication, regulatory approval or commercial outcome.
Scientific leadership
Dr Chathyushya K B
Founder, MD & CEO — PhD Microbiology, ICMR-NIN; PGDM Bioinformatics; Advanced Diploma in Patent Law, NALSAR; 15+ years' scientific experience.
The scientific team reviews the question, sample plan and interpretation so that the report explains what the evidence supports and where further work is needed.
Read the founder's scientific profile →Plan your enquiry
Explore feasibility, timing and a quotation
Choose the closest topic for feasibility review. These enquiry topics do not confirm that a method, facility or platform is available, and are not a confirmed service, price or completion date.
Loading choices. The website enquiry form remains available on this page.
Only enter your city and state. If provided, these are included in the prepared message; do not enter names, contact details or patient information here.
Estimated turnaround: Timing depends on the method, sample suitability, workload and reporting requirements. The team will confirm an estimate after review.
Next step: Share a non-confidential outline so the team can assess the question, requirements and next steps.
Methods, availability, fees, procurement and execution sites are confirmed for each project. In-vivo studies require applicable approvals and an authorised external partner facility under an MoU. Publication or admission is never guaranteed.
Share only a non-confidential outline initially. Do not include patient identifiers, unpublished protocols or sensitive sample details in WhatsApp. Request a suitable confidential channel before sharing them.
Select one option in each group to prepare your WhatsApp message. The website form is separate; please repeat the details there if you use it.
Request a service quotation
Start with the question your data must answer.
Share a non-confidential research objective, methods of interest, sample type, intended research use and timeline. Do not send patient identifiers, confidential records or materials before written acceptance.
Choose the enquiry category that fits your request in the form, such as PhD, medical research, academic project or laboratory service.
Send a non-confidential outline first. Do not include patient identifiers or upload proprietary sequence data in this enquiry. Ask for an NDA and an approved transfer route when needed.
Nacharam, Hyderabad laboratory — approximately a 12-minute walk from Habsiguda Metro. Contact us before dispatching samples; collection, preservation and transport instructions depend on the approved assay.
Contract and bulk enquiries: +91 8977681985 · Technical scope: +91 8978792215
Related services
Choose the service that matches the scientific question.
In-vivo research feasibility
Review external facility, model and approval requirements.
Whole genome sequencing
Discuss long-read microbial and other research sequencing requirements.
Pharma and analytical research
Discuss research-use cell, chemistry, molecular and preclinical feasibility.
Pan-India sample and remote research
Request written sample acceptance and transport instructions.
In-vitro research
Review research-use cellular and molecular methods.
Questions
Frequently asked questions
Can I enquire about scRNA-seq, snRNA-seq or spatial transcriptomics?
+
Yes. These are feasibility enquiries, not confirmed platform availability. Share the tissue type, research objective, proposed collection and analysis requirements without identifiers. The team must verify specialist expertise, instrument access, processing and the receiving facility before accepting a project.
How should fresh or cryopreserved tissues be shipped?
+
Do not send tissue until the receiving laboratory has accepted it in writing. Collection, preservation, timing, packaging, permits and carrier rules depend on the specimen, assay and facility. Obtain project-specific instructions and required institutional consent and biosafety approvals first.
Can medical devices or dental scaffolds be considered for ISO 10993 testing?
+
You may request a feasibility review. The device, extraction approach, endpoints, current relevant ISO standards, laboratory accreditation and intended regulatory use require separate confirmation. A research-use discussion is not a certified biocompatibility or regulatory report.
Can you assess OECD genotoxicity and animal studies?
+
Ames, comet, OECD 474/475 and other methods can be discussed. Capability, applicable guideline, laboratory status and intended use must be verified for each project. Eligible animal studies may be coordinated at an external facility under an MoU only after its capability and applicable ethical and regulatory approvals are confirmed.
Are ADME, PK/PD and bioavailability studies available?
+
Provide a non-confidential compound and research question for assessment. Cell models, analytical platforms, animal-study site, data outputs and any regulatory requirements must be verified. No assay, model, turnaround or outcome is guaranteed.
Can I request zebrafish or C. elegans models?
+
You can discuss the proposed model, endpoints and intended use. Species, life stage, facility capability, approvals and relevant guideline applicability must be checked before a scope is accepted.
Can harvested animal tissues be used for multi-omics?
+
A proposed tissue-to-omics workflow requires coordination between the approved animal-study facility and a separately verified receiving and analytical laboratory. Permissions, collection, preservation, quality and data transfer must be agreed before any material is sent.
Are these clinical diagnostics or guaranteed academic outcomes?
+
No. This page describes research feasibility, not clinical diagnosis or patient care. Scholars and supervisors retain academic ownership and authorship; we do not fabricate data, sell authorship or ghostwrite. Publication, admission, patent grant and regulatory acceptance are not guaranteed.